These authors engineered a nano formulation consisting of human serum albumin possessing the LRP-1-binding peptide and B5 for tumor targeting, along with 5-FU and Cy7 (Cy7–B5–HSA–5-FU). This evidence concerns the gene ALB and neoplasm.